Key facts
- This page summarizes Fabiana Fedeli's Form 4 filing for RELMADA THERAPEUTICS, INC. (RLMD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Dec 2025, 09:29.
Fabiana Fedeli - 12 Dec 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)
- Reporting relationship
- Director
- Issuer ticker
- RLMD
- Reported as of
- 12 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2025, 09:29:40 UTC
- Prior SEC filing
- 30 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Fabiana Fedeli
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fabiana Fedeli filed Form 4 for RELMADA THERAPEUTICS, INC. (RLMD) on 16 Dec 2025.
Change
- Previous filing in this sequence was filed on 30 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001961902
Primary reporting owner
Fedeli Fabiana
- Relationship
- Director
- Address
- C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES
- Signature
- /s/ Fabiana Fedeli
- Signature date
- 16 Dec 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RLMD
transaction
Derivative
Stock Appreciation Rights
Award
- Transaction value
- $0
- Shares
- +164,000
- Change %
- Price
- $0.000000
- Shares after
- 164,000
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 164,000
- Exercise price
- $4.06
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.